Latest Breaking News On - Atherosclerotic cardiovascular disease - Page 1 : vimarsana.com

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Indiana GOP Congressional Primary Won by Woman Who Passed Away 2 Months Ago

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]

Novartis Pharma AG: New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on...

Lp(a) Tied to Higher CVD Events; Risk Reduction With IPE

New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.

Clinical Quiz: Nonstatin Therapies for LDL-C Lowering in Special Populations

This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.

REDUCE-IT Lp(a) Analysis Details Icosapent Ethyl Effect on MACE Across Lp(a) Range

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).